GenoMed Applies for Listing on American Stock Exchange
July 06, 2004 09:30:00 AM ET
ST. LOUIS, July 6 /PRNewswire-FirstCall/ -- GenoMed, Inc. ("the Company" or "GenoMed") (Pink Sheets: GMED), a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it has applied to be listed on the American Stock Exchange.
The Company expects to hear from the Exchange in 6-8 weeks about the status of its application.
Dr. David Moskowitz, CEO and Chief Medical Officer of GenoMed, remarked, "This is a major step in continuing the momentum we have recently established. Moving from the Pink Sheets will increase investor confidence, improve liquidity, and most importantly, allow for increased institutional investment. Many large investors are not permitted to buy Pink Sheets securities."
About GenoMed
GenoMed is a Next Generation DM(TM) [Disease Management] company which uses knowledge of disease-causing genes to improve patient outcomes. The Company's goal this summer is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" link at genomedics.com .
news.moneycentral.msn.com |
